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ABSTRACT
Infections are a common complication of allogeneic bone marrow transplantation and the leading cause of
transplantation-related mortality. It had been hypothesized that transplantation following nonmyeloablative pre-
parative regimens would result in fewer infections by causing less mucosal injury, less graft-versus-host disease, and
allowing earlier immune reconstitution. We have retrospectively reviewed the infectious complications of 65
consecutive patients with advanced hematologic malignancies who underwent bone marrow transplantation using
a novel preparative regimen consisting of cyclophosphamide, thymic irradiation, and in vivo T-cell depletion.
Cytomegalovirus (CMV) infection occurred in 52% of cases in which the donor or recipient had evidence of prior
CMV exposure. Using a strategy of preemptive therapy and secondary prophylaxis with ganciclovir, no CMV
disease occurred. Infections with gram-positive bacteria predominated over the first 100 days after bone marrow
transplantation. Thereafter, the relative proportion of gram-negative infections increased without a significant
increase in episodes of neutropenia. The rate of bacterial infections was not influenced by relapse of the underlying
malignancy. Seven patients developed infections with Aspergillus species, which was the most common infectious
cause of death in these patients. Infections with viruses other than CMV (n10) and with protozoan organisms
(n2) also occurred. The use of HLA-mismatched donors, the occurrence of grade II-IV acute graft-versus-host
disease, and treatment with corticosteroids did not influence the risk of CMV or bacterial or fungal infections in
patients who underwent transplantation following this preparative regimen. Overall, the incidence and spectrum of
infections in this series was similar to the reported incidence of infections following conventional myeloablative
allogeneic stem cell transplantation. We conclude that a quantitative T-cell deficiency in these extensively T-cell
depleted patients may be a risk factor for infection, even in the absence of graft-versus-host disease.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Despite major advances in supportive care, infec-
tions almost invariably occur after an allogeneic bone
marrow transplantation and remain a cause of signif-
icant morbidity and mortality [1]. Infections are re-
ported to account for up to 63% of deaths in alloge-
neic transplantation recipients at the time of autopsy
[2]. Susceptibility to infection is closely linked to the
degree of donor and host histocompatibility, graft-
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versus-host disease (GVHD), and immunosuppres-
sion. Although infections with common bacterial
organisms occur in this setting, transplantation recip-
ients are uniquely susceptible to infection with atypi-
cal or opportunistic pathogens such as cytomegalovi-
rus, fungi, and atypical mycobacteria. Numerous
studies designed to deﬁne the role of antimicrobial
prophylaxis in this patient population have been car-
ried out, and extensive guidelines based on these stud-
ies have recently been adopted [3].
Nonmyeloablative stem cell transplantations have
been carried out in a number of centers for patients
with advanced or refractory hematologic malignancies
[4-6]. The potential for reduced toxicity with these
nonmyeloablative regimens makes them an attractive
treatment option in this frequently debilitated group
of patients. Furthermore, a reduced duration of neu-
tropenia, earlier withdrawal of immunosuppression,
and the potential for earlier and more complete im-
mune reconstitution could result in fewer posttrans-
plantation infectious complications.
At our center, nonmyeloablative stem cell trans-
plantations have been carried out using a novel pre-
parative regimen consisting of high-dose cyclophos-
phamide, thymic irradiation, and in vivo T-cell
depletion using antithymocyte globulin or anti-CD2
monoclonal antibody therapy followed by HLA-
matched or haploidentical donor bone marrow trans-
plantation. Prophylactic donor lymphocyte infusions
are administered to patients without GVHD approx-
imately 35 days posttransplantation, after resolution of
regimen-related tissue injury and establishment of
mixed donor-host lymphoid chimerism, in an effort to
induce a more potent immune-mediated antitumor
response. This regimen has been previously reported
to reliably induce mixed chimerism after HLA-
matched or partially mismatched donor stem cell
transplantation, often with signiﬁcant antitumor re-
sponses among patients with advanced hematologic
malignancies [7,8].
Given the potential for reduced toxicity and im-
proved immunocompetence of recipients of nonmy-
eloablative stem cell transplantations, we undertook a
review of the infectious complications in 65 recipients
of these transplants in our center.
PATIENTS AND METHODS
Patients
Sixty-ﬁve patients with advanced hematologic ma-
lignancies received a nonmyeloablative bone marrow
transplantation between April 1997 and December
2000. These patients were analyzed for infectious
complications through May 2001. All patients under-
went transplantation on protocols approved by the
Massachusetts General Hospital (Boston, MA) Sub-
committee for Human Studies, and all subjects gave
written informed consent. Eligibility criteria included
a diagnosis of advanced hematologic malignancy,
physiologic age 70, Eastern Cooperative Oncology
Group performance status of 0, 1, or 2, and adequate
organ function. Patients and donors were HLA typed
using serologic methods for class I antigens and high-
resolution polymerase chain reaction-based methods
for HLA-DR. Before transplantation, donors and re-
cipients were screened for serologic evidence of expo-
sure to Toxoplasma gondii, cytomegalovirus (CMV),
herpes simplex virus 1 and 2, hepatitis B and C, human
T-lymphotrophic virus 1 and 2, and the human im-
munodeﬁciency virus types 1 and 2.
Conditioning Therapy
Conditioning chemotherapy consisted of cyclo-
phosphamide 50 mg/kg/day for 3 (n53) or 4 (n12)
days before transplantation, from day6 or5 to day
3. Thymic irradiation was given at a dose of 700 cGy
on day 1 to all patients who had not had prior
mediastinal radiotherapy (n44). T-cell depleting an-
tibodies were used in all cases. Antithymocyte globulin
(ATG; ATGAM, Pharmacia-Upjohn, Kalamazoo,
MI) was initially given at a dose of 30 mg/kg on days
2, 1 and 1 (n8). Because of toxicity, the dose
was reduced to 15 mg/kg/day on days 1, 1, 3,
and 5 (n27). The ATG dose was subsequently
changed to 20 mg/kg/day on days 1, 1, 3,
and 5 (n22). MEDI-507 (BioTransplant Inc,
Charlestown, MA), a humanized anti-CD2 monoclo-
nal antibody, was given to 8 recipients of HLA 2- or
3- antigen mismatched transplants. Four patients re-
ceived a test dose of MEDI-507 0.1 mg/kg on day2,
followed by 0.6 mg/kg on days 1, 0, and 1. Four
patients received a test dose of MEDI-507 0.1 mg/kg
on day 7 and 0.6 mg/kg doses on days 6 and 5.
Bone marrow was collected as described on day 0 and
infused over 1 to 2 hours [7].
Graft-versus-Host Disease Prophylaxis and
Treatment
Cyclosporine 5 mg/kg/day was started by contin-
uous infusion on day 1. The dose was reduced on
day 4 to 3 mg/kg/day and adjusted to maintain
whole blood levels within the therapeutic range (200-
300 ng/mL). Dosage adjustments were made for sig-
niﬁcant renal dysfunction. Cyclosporine (Sandim-
mune; Novartis Pharmaceuticals Corp, East Hanover,
NJ) was given twice daily by mouth at a starting dose
of 12 mg/kg/day once oral medications were tolerated.
In the absence of acute GVHD, cyclosporine was
tapered and discontinued by approximately day 35
in preparation for a donor lymphocyte infusion.
Engraftment syndrome [9] and acute GVHD were
treated with intravenous methylprednisolone 1 to 2
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mg/kg/day in 2 divided doses for recipients of HLA-
matched bone marrow stem cells. A starting dose of
intravenous methylprednisolone of 2 to 10 mg/kg/day
was used in recipients of partially mismatched bone
marrow grafts.
Donor Leukocyte Infusion
Donor peripheral blood mononuclear cells were
collected by apheresis on or before day35. An initial
infusion on or after day 35 consisting of 1  107/kg
CD3 cells was given to 20 transplant recipients with-
out evidence of acute GVHD for conversion from
mixed chimerism to full donor chimerism. A second
infusion of 1 to 5  107/kg CD3 cells was given on
day 56 per protocol to 3 patients. The protocol was
subsequently amended to allow a second infusion of
donor lymphocytes only for patients without acute
GVHD in whom donor chimerism was less than 90%
at 4 weeks after the ﬁrst infusion.
Antimicrobial Prophylaxis
Surveillance cultures of blood, stool, urine, and
oropharynx were taken at the time of admission and
then weekly until discharge. Patients used chlorhexi-
dine mouthwash for mouth care and showered with
chlorhexidine daily.
On admission, patients were started on co-trimox-
azole and an oral ﬂuoroquinolone daily for prevention
of Pneumocystis carinii and bacterial infections, respec-
tively. Cotrimoxazole was continued until day 1 and
was then given 3 times weekly from the time of en-
graftment. Patients unable to take cotrimoxazole re-
ceived intravenous pentamidine 5 mg/kg monthly or
oral atovaquone. Oral ﬂuconazole 400 mg was given
on day 1, and then reduced to 200 mg orally daily.
Acyclovir 250 mg/m2 every 8 hours intravenously was
started on day 1 and then changed to the oral route
of administration after engraftment had been
achieved. P carinii prophylaxis, ﬂuconazole and acy-
clovir, were continued until patients showed no fur-
ther evidence of GVHD.
Supportive Care
An indwelling double-lumen silastic central ve-
nous catheter was placed before transplantation.
Dressings were changed 3 times weekly and the cath-
eter site was examined for signs of infection on a daily
basis. Topical antibiotic ointment was applied to the
site with each dressing change. All patients were cared
for in high-efﬁciency particulate air ﬁltered or laminar
airﬂow rooms. Reverse isolation was continued until
the time of neutrophil engraftment, deﬁned as the ﬁrst
day of absolute neutrophil count 500/L. Fever
higher than 100.5° F in neutropenic patients was
treated empirically with broad-spectrum antibiotics,
usually ceftazidime and vancomycin, and antibiotics
were adjusted based on microbial sensitivity testing for
patients with positive cultures. Antibiotics in febrile
neutropenic patients were continued until the time of
engraftment.
Cases in which both donor and recipient were
negative for CMV antibodies received blood that was
serologically negative for CMV. All transplantation
recipients were monitored weekly using a CMV pp65
antigenemia assay. Two slides were examined and
patients with 1 or more positive cells were treated with
ganciclovir as follows. Induction consisted of ganci-
clovir 5 mg/kg intravenously 2 times daily for 10 days
to 2 weeks followed by ganciclovir 5 mg/kg intrave-
nously daily until 2 consecutive weekly negative CMV
pp65 antigenemia assays were obtained. Patients were
maintained on oral ganciclovir 1000 mg twice daily for
at least the ﬁrst 6 months posttransplantation or until
they no longer required treatment with immunosup-
pressive medications. Doses were adjusted clinically
according to renal function and blood counts. Patients
who experienced myelosuppression while on ganciclo-
vir could be treated with granulocyte colony-stimulat-
ing factor (Neupogen; Amgen Thousand Oaks, CA) as
clinically indicated. In cases where CMV antigenemia
failed to clear in a timely manner or when patients
were unable to tolerate ganciclovir, anti-CMV hyper-
immune globulin could be administered.
Intravenous immunoglobulin 0.5 g/kg was given
monthly to patients with IgG levels of 400 mg/dL.
Statistical Analysis
Data on infection, relapse, and mortality were
collected prospectively for use in this analysis. An
infectious episode was deﬁned on the basis of positive
culture or antigen tests. Positive bacterial or fungal
cultures from normally sterile sites were considered to
represent an infection, while cultures from nonsterile
sites were considered to represent an infection only in
the presence of corroborative clinical signs. Two cul-
tures positive for the same organism obtained from
the same site within a 2-week period were considered
to represent a single infection. Aspergillus and Nocardia
were exceptions to this: 2 cultures positive for either of
these organisms were considered to represent the
same infection, regardless of the time or site of sam-
pling. The day of onset of acute GVHD was taken as
the day on which the ﬁrst biopsy consistent with this
diagnosis was sent. In 3 cases, a diagnosis of grade
II-IV acute GVHD was made without histologic con-
ﬁrmation. In these cases, the date of onset is taken as
the day on which treatment for acute GVHD was
instituted. Infectious episodes for patients who expe-
rienced engraftment failure, as indicated by a return to
fully recipient bone marrow chimerism, were not cen-
sored, although these patients were no longer consid-
ered to be at risk for GVHD. The actuarial rates of
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GVHD onset, ﬁrst CMV infection, and ﬁrst bacterial
infection were estimated by the Kaplan-Meier
method. Their associations with HLA matching and
CMV serostatus were analyzed by the log-rank test,
while the effect of GVHD was modeled as a time-
varying covariate in a proportional hazards regression.
Poisson regression was used to examine the relation-
ship between the incidence rates of CMV infection,
bacterial infection, and Aspergillus infection with the
onset of GVHD, initiation of steroids, or relapse. In
the analysis of the effect of GVHD on the incidence of
infection, the follow-up time and infectious episodes
before the onset of GVHD and after loss of chimerism
contribute to the risk in the no-GVHD group. This
approach is analogous to the treatment of GVHD as a
time-dependent covariate by Osarogiagbon et al. [10],
while allowing for multiple infectious episodes per
patient.
RESULTS
Sixty-ﬁve patients underwent nonmyeloablative
bone marrow transplantation between April 1997 and
December 2000. Pretransplantation characteristics are
shown in Table 1. In the case of HLA-mismatched
transplants, donors were mismatched for 1 (n5), 2
(n15), or 3 (n2) HLA antigens in the GVHD
direction. Patients were extensively pretreated before
undergoing transplantation. Median number of prior
chemotherapy regimens was 3 (range, 0-8) and 22%
had prior autologous stem cell transplantations. At the
time of transplantation 64 of 65 patients had chemo-
therapy-refractory disease or had received a prior au-
tologous stem cell transplantation. One patient was in
partial remission following salvage chemotherapy for
non-Hodgkin’s lymphoma. Median time from diag-
nosis was 19.2 months (range, 5-115.8 months) for
recipients of fully matched bone marrow transplants
and 18.7 months (range, 4.7-185 months) for recipi-
ents of mismatched bone marrow.
One year after transplantation, the cumulative in-
cidence of grade II-IV acute GVHD or de novo ex-
tensive chronic GVHD was 55%. Median actuarial
time to onset of GVHD was 188 days. Graft rejection
occurred in 19 of 65 patients (29%) a median of 44
days (range, 20-143 days) after transplantation. Autol-
ogous reconstitution occurred promptly in all patients
who experienced graft rejection. Thirty-nine patients
(60%) showed evidence of disease progression a me-
dian of 119 days (range, 0-908 days) posttransplanta-
tion.
Cytomegalovirus
Twenty-nine of 43 recipients (67%) of matched
bone marrow grafts were at risk for CMV infection
while 13 of 22 recipients (59%) of mismatched grafts
were at risk. Overall, 52% of patients at risk experi-
enced reactivation of latent CMV infection. Eighty-
two percent of patients who reactivated CMV did so
for the ﬁrst time in the ﬁrst 60 days. All patients who
reactivated did so for the ﬁrst time within 100 days of
transplantation. Cytomegalovirus infection occurred a
median of 38.5 days (range, 11-98 days) after trans-
plantation in recipients of HLA-matched bone mar-
row and after a median of 25 days (range, 21-87 days)
in recipients of HLA-mismatched bone marrow
(P.823). Other pretransplantation variables, such as
cyclophosphamide dose (P.218), use of thymic irra-
diation (P.141), use of ATG or MEDI-507 for in
vivo T-cell depletion (P.672), or use of therapeutic
donor lymphocyte infusion (DLI) (P.807), did not
inﬂuence the development of CMV infection. Patients
who received prophylactic DLI were twice as likely to
develop CMV infection after transplantation
(P.021).
Nine patients (41%) required treatment for a sec-
ond episode of CMV infection at a median of 122 days
(range, 56-392 days) after transplantation. Four pa-
tients were antigenemic on a third and fourth occasion
between 165 and 351 days and 223 and 483 days,
respectively. Recipients of mismatched transplants
cleared CMV antigenemias more slowly than did re-
cipients of HLA-matched transplants, at a median of
14 days (range, 1-86 days) versus 5 days (range, 1-18
days) (P.0497). The peak number of white blood
cells positive for CMV pp65 antigen was 3 (range,
1-10) for recipients with HLA-matched donors, versus
9 cells (range, 1-274) for those with mismatched do-
nors (P.117).
Donor and recipient serostatus was a strong pre-
dictor of CMV infection posttransplantation (Figure
1). The highest incidence of CMV infection occurred
in cases in which both donor and recipient were sero-
logically positive for CMV antibodies. In this situa-
Table 1. Patient Characteristics at Time of Transplantation
HLA Matched HLA Mismatched
No. of Patients 43 22
Median age (range) 44 (22–62) 35 (16–58)
Percent male 60% 64%
Diagnosis
NHL 26 (60%) 17 (77%)
HL 6 (14%) 1 (4.5%)
AML 5 (12%) 2 (9%)
ALL 1 (2%)
CLL 4 (9%) 1 (4.5%)
MM 1 (2%) 1 (4.5%)
Prior autologous
transplant 13 (30%) 1 (4.5%)
Abbreviations NHL, non-Hodgkin lymphoma; HL, Hodgkin
lymphoma; AML, acute myeloid leukemia; ALL, acute lymphoblas-
tic leukemia; CLL, chronic lymphocytic leukemia; MM, multiple
myeloma.
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tion, 82% of recipients became viremic at a median of
40 days (range, 11-98 days) posttransplantation. This
compares with 43% of patients experiencing infection
if only 1 member of the donor–recipient pair was
positive for CMV antibodies (P.015). Cytomegalo-
virus infection was less likely if the recipient was CMV
negative. Infection occurred in 32% of CMV-negative
recipients who received transplants from CMV posi-
tive donors, compared with 76% of CMV-positive
recipients who received transplants from donors who
were either CMV positive or negative (P.002). The
rate of infection of seropositive recipients was not
affected by the serostatus of the donor (P.827). Me-
dian time to infection was signiﬁcantly shorter when
both donor and recipient were positive for CMV as
compared with when only the donor was CMV posi-
tive (40 days [range, 11-98 days] v unreached with a
plateau of 32% of patients reactivating after 87 days
[range, 50-87 days]; P.002). No CMV-negative pa-
tient receiving a transplant from a CMV-seronegative
donor became viremic following transplantation.
Cytomegalovirus reactivated 24 times over 7002
patient-days of follow-up of patients without GVHD
and 15 times over 6874 patient-days of follow-up of
patients with GVHD (P.107). There were 28 epi-
sodes of viremia in at-risk patients treated with ste-
roids over 9342 patient-days of follow-up, compared
with 11 episodes of viremia over 4534 patient-days of
follow-up among patients not receiving treatment
with steroids (P.552).
Twenty-two patients received treatment for CMV
infection. Two of these cases were intermittently lost
to follow-up, leaving insufﬁcient information to eval-
uate the tolerability of CMV treatment. During the
induction phase of ganciclovir therapy, 3 patients de-
veloped neutropenia and required treatment with
granulocyte colony-stimulating factor. In no case was
ganciclovir dosing reduced during induction because
of myelosuppression. Two patients were treated with
CMV hyperimmune globulin in addition to ganciclo-
vir during induction because of delayed clearance of
CMV antigen. Foscarnet was added to ganciclovir in 1
of these cases, although viral sensitivity testing subse-
quently conﬁrmed sensitivity to nucleoside analogues.
Three patients died during ganciclovir induction, 2
from progression of their malignancies on days 40
and 41 and 1 from disseminated aspergillosis on day
107. Fourteen patients received maintenance ther-
apy with oral ganciclovir. Information on the course
of maintenance therapy was unavailable in 2 patients
known to have received it. Dosage adjustment was
required for myelosuppression in 6 of the 12 remain-
ing patients. Three patients required granulocyte col-
ony-stimulating factor, and maintenance therapy had
to be stopped in 2 cases. One patient received treat-
ment with CMV hyperimmune globulin for mainte-
nance in addition to reduced-dose ganciclovir. Three
patients became viremic while on maintenance ganci-
clovir, and in all cases viremia resolved with increased
doses of oral ganciclovir. In all cases of breakthrough
viremia the ganciclovir dose had been reduced because
of myelosuppression. Cytomegalovirus disease did not
occur in any of these patients.
Bacterial Infections
Overall, 87 cultures were positive for bacterial
organisms in 79 separate infections. These included
53 infections with gram-positive organisms alone and
25 infections with only gram-negative organisms. One
patient had a mixed infection with both a gram-posi-
tive and a gram-negative organism (Table 2). Coagu-
lase negative Staphylococcus was the most commonly
identiﬁed organism, causing 33 infections. These in-
clude 26 bacteremias, which occurred at a median of
64 days (range, 3-383 days) posttransplantation. Two
wound swabs became positive for coagulase negative
Staphylococcus and 1 patient was diagnosed with osteo-
myelitis and secondary septic arthritis caused by this
organism on day 71. The latter patient was also
bacteremic with coagulase-negative Staphylococcus on
day 111. Central venous catheter tip cultures were
positive for coagulase-negative Staphylococcus on 4 oc-
casions.
The spectrum of bacterial infections in the post-
transplantation period is shown in Table 2. The risk of
developing bacterial infection remained present well
Figure 1. First CMV infection of exposed patients by donor/
recipient serostatus. Kaplan-Meier product-limit estimates of the
actuarial risk of experiencing a ﬁrst episode of CMV viremia for
cases in which donor and recipient are both positive (/, actuarial
risk 82%), donor is negative and recipient is positive (-/, actuarial
risk 63%), or donor is positive and recipient is negative (/-,
actuarial risk 32%). Cases in which neither donor nor recipient was
positive are not indicated because no such patients were found to
have CMV viremia.
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after 100 days posttransplantation, and infections with
low virulence organisms occurred well into the second
year. For example, 5 cultures from 3 patients showed
Nocardia nova species at a median of 189 days (range
165-977 days) posttransplantation. Two of these were
diagnosed on blood culture, 1 on sputum culture, and
1 on culture of pleural ﬂuid in a patient with a large
pleural effusion. One of these patients was subse-
quently found to also have meningitis with Nocardia. A
recipient of a mismatched transplant presented with
headache and mental status changes on day 427. A
culture of cerebrospinal ﬂuid was positive for Listeria
monocytogenes. Among patients surviving for more than
100 days, the relative proportion of gram-negative
infections increased dramatically, accounting for 47%
of infections during this period. However, neutrope-
nia was present in only 2 patients with gram-negative
infections beyond day 100.
The sites of bacterial infection are shown in Table
3. While bacteremia remained common even late
posttransplantation, the relative frequency declined
with time. An increase in the frequency of nonbacte-
remic bacterial infections, particularly involving the
lung, skin, and soft tissues, can be appreciated.
The time to ﬁrst bacterial infection was not af-
fected by the degree of HLA matching between donor
and recipient and was 109 days (range, 3-836 days) for
the recipients of matched stem cells and 75 days
(range, 3-192 days) for the recipients of mismatched
transplants (P.403). Other pretransplantation vari-
ables, such as cyclophosphamide dose (P.997), use of
MEDI-507 or ATG for T-cell depletion (P.248),
and the use of prophylactic DLI (P.456) did not
inﬂuence the rate of bacterial infections. There was a
49% increase in bacterial infections among patients
who were given thymic irradiation before undergoing
transplantation, although this association was not sta-
Table 2. Causes of Bacterial Infections in Recipients of Nonmyeloablative Stem Cell Transplants
Days Posttransplant
0–30 31–60 61–100 >100
Evaluable patients (n) 65 61 54 44
No. of patients with
bacterial infections (%)
12 (18%) 13 (21%) 11 (20%) 21 (48%)
No. of bacterial infections 14 14 13 38
Gram-positive 12 10 11 20
Organisms (n) CNS (6) CNS (9) CNS (8) CNS (10)
Streptococcus mitis (2) Corynebacterium and S aureus (2) S aureus (2)
Enterococcus (1) Peptostreptococcus (1) Bacillus and CNS (1)
Clostridium difficile colitis
(2)
Enterococcus (2)
Strep. bovis (1)
Clostridium innoccuum (1)
Strep. Pneumoniae (1)
Nocardia (3)
Listeria monocytogenes (1)
Gram-negative 2 4 2 18
Organisms (n) Pseudomonas (1) Klebsiella (1) Campylobacter (1) Pseudomonas (5)
Roseomonas (1) Pseudomonas (1) Pseudomonas (1) Acinetobacter (1)
Campylobacter (1) Klebsiella (2)
Xanthomonas and
Klebsiella (1)
Serratia (1)
E coli (1)
Bacteroides (2)
Campylobacter (2)
Hemophilus influenzae (2)
Pseudomonas and
Klebsiella (1)
Acinetobacter,
Pseudomonas and
Enterococcus (1)
Abbreviation: CNS, coagulase-negative staphylococcus.
Table 3. Sites of Bacterial Infections in 65 Recipients of
Nonmyeloablative Bone Marrow Transplants
Days Posttransplant
0–30 31–60 61–100 >100
Bacteremia 11 11 10 18
Central venous catheter 2 1 3
Gastrointestinal 2 1 2
Skin/soft tissue 1 1 1 3
Genitourinary tract 1 1
Osteomyelitis 1
Pneumonia 1 9
Empyema 1
Meningitis 1
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tistically signiﬁcant (P.086). Many of these addi-
tional infections occurred within the ﬁrst 30 days (11
episodes v 3 episodes; P.235), possibly because of an
increase in mucositis in the group given thymic irra-
diation.
The rate of occurrence of bacterial infections was
not inﬂuenced by the presence of GVHD. Of the 79
bacterial infections, 40 occurred over 10 287 patient-
days of follow-up of patients with GVHD. In com-
parison, 39 occurred over 11 251 patient-days of fol-
low-up of patients without GVHD (P.610). Graft
rejection was associated with a decrease in the number
of bacterial infections, with 66 bacterial infections
occurring over 15 845 patient-days of observation in
patients with fully donor chimerism and 13 such in-
fections over 5693 patient-days after the grafts were
rejected (P.048).
The rate of bacterial infections was not affected by
relapse: 26 bacterial infections after relapse occurred
over 6306 patient-days of follow-up, compared with
53 such infections over 15 232 patient-days of fol-
low-up before relapse (P.478).
Fungal Infections
Seven patients developed Aspergillus infections a
median of 93 days (range, 40-165 days) posttransplan-
tation; 5 of these patients died a median of 108 days
(range, 57-197 days) after transplantation. In 5 cases,
Aspergillus colonies were isolated from sputum sam-
ples, in 1 case from bronchoalveolar lavage ﬂuid, and
in another case widespread angioinvasive Aspergillosis
was found on postmortem examination. Isolates con-
sisted of Aspergillus fumigatus on 5 occasions and As-
pergillus niger and Aspergillus versicolor on 1 occasion
each. Five patients had abnormal chest imaging stud-
ies consistent with pneumonia at the time sputum
cultures were obtained. One patient with fungal sinus-
itis had a normal chest x-ray but computed tomogra-
phy scans of the paranasal sinuses demonstrated opaci-
ﬁcation and air-ﬂuid levels. Two patients were alive at
the time of analysis, 398 and 350 days posttransplan-
tation. Five Aspergillus infections occurred in patients
undergoing treatment for GVHD, 1 patient devel-
oped biopsy-proven GVHD 8 days following the iso-
lation of Aspergillus, and 1 patient with steroid-resis-
tant acute GVHD was found to have aspergillosis and
persistent lymphoma on postmortem examination. As-
pergillosis was the most common infectious cause of
death in this group of patients.
The only pretransplantation variable associated
with the development of Aspergillus infection was the
use of high-dose ATG for T-cell depletion. The use
of 20 or 30 mg/kg ATG was associated with a 6-fold
increase in the probability of developing such infec-
tions (P.041). Transplantation from mismatched do-
nors (P.389), cyclophosphamide dose (P.374), use
of thymic irradiation (P.433), use of MEDI-507 or
ATG for T-cell depletion (P.288), and choice of
DLI strategy (prophylactic, P.374; therapeutic,
P.304) did not inﬂuence the probability of develop-
ing Aspergillus infection.
The association of Aspergillus infection and
GVHD failed to achieve statistical signiﬁcance
(P.136). In 4 cases, GVHD was refractory to steroid
therapy and was treated with antithymocyte globulin
or anti-CD25 monoclonal antibody therapy or, in 1
case, both agents.
One patient developed symptoms of pneumonia
and had an abnormal chest x-ray 5 days after trans-
plantation. Cryptococcus neoformans was isolated from
the sputum in this case. A leg ulcer discovered on day
8 posttransplantation was caused by infection with
Alternaria species. This patient is alive and free of
disease 1177 days after undergoing HLA-matched
stem cell transplantation for chemorefractory non-
Hodgkin lymphoma.
Other Viral Infections
Ten viral infections other than CMV were docu-
mented. Adenovirus cystitis occurred in 3 patients at a
median of 73 days (range, 20-252 days) after trans-
plantation. Infections with herpesviruses occurred on
3 occasions, and included perianal and oral herpes
simplex 1 on days 0 and 444, respectively. One
patient developed a dermatomal varicella-zoster virus
infection on day 259. All herpesvirus infections
other than CMV occurred in recipients of matched
transplants. Respiratory virus infections were diag-
nosed in 4 patients at a median of 322 days (range,
12-1064 days) after transplantation. These include 2
parainﬂuenza and 2 inﬂuenza B infections, diagnosed
on nasal swab in 2 cases and from sputum and bron-
choalveolar lavage ﬂuid in 1 case each. Viral pneumo-
nia was diagnosed only in the case in which parainﬂu-
enza was recovered on bronchoscopy.
Protozoan Infections
Two patients developed infections with protozoan
organisms. One patient developed fever and right eye
pain 402 days after an HLA-matched transplant for
non-Hodgkin lymphoma. Pretransplantation serology
was equivocal for Toxoplasma gondii on 1 occasion and
negative on retesting. This patient required treatment
with anti-CD25 monoclonal antibody for treatment of
GVHD on days 115 and 176 posttransplantation. Ret-
inal examination showed chorioretinitis and retinal
detachment. A clinical diagnosis of toxoplasmic cho-
rioretinitis was made and treatment was started with
pyrimethamine, clindamycin, and folinic acid. The
patient underwent vitreous biopsy but specimens were
insufﬁcient to conﬁrm the etiology of the eye pain.
The patient failed to recover vision in that eye.
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A second patient developed diarrhea 298 days fol-
lowing an HLA-matched transplant for non-Hodgkin
lymphoma. Stool examination was positive for Giardia
lamblia and the patient responded to treatment with
metronidazole. This patient never developed GVHD
and was never treated with steroids despite receiving 2
donor leukocyte infusions on days 35 and 57 for per-
sistent disease.
DISCUSSION
Despite the hopes of earlier and more complete
immune reconstitution following nonmyeloablative
allogeneic stem cell transplantation, the recipients in
this study had a very high incidence of opportunistic
infections. Furthermore, we have documented that
the risk of infection persists for an extended period
following transplantation, with Listeria meningitis di-
agnosed 427 days after transplantation and CMV in-
fection occurring as late a 483 days posttransplanta-
tion. Infections with a broad range of opportunistic
pathogens, including CMV, fungal organisms, and
infections with low-virulence bacteria such as Nocardia
nova and Listeria monocytogenes were seen. In some
cases, these infections may reﬂect the advanced disease
state of our transplantation population because some
patients experienced infections with opportunistic
pathogens such as Alternaria, Cryptococcus neoformans,
and Roseomonas within the ﬁrst week after transplan-
tation. The range of infections observed in this group
of patients is similar to that of recipients of traditional
myeloablative bone marrow transplantations.
Cytomegalovirus infection is the most common
opportunistic infection following allogeneic stem cell
transplantation. Risk factors for reactivation of latent
CMV infection include GVHD, treatment with im-
munosuppressive medications, and donor and recipi-
ent serostatus before transplantation. The rate of in-
fection with CMV following myeloablative stem cell
transplantation has been reported to be between 38%
and 58% [11-14]. Using more sensitive methods of
detection, the rate of infection in at-risk patients un-
dergoing myeloablative stem cell transplantation has
been reported to be as high as 79% [15]. In a group of
21 patients undergoing nonmyeloablative stem cell
transplantation for treatment of hematologic malig-
nancies and solid tumors, the rate of CMV infection
was 65% and occurred at a median of 31 days follow-
ing transplantation. The transplantation preparative
regimen in this series included both antithymocyte
globulin and ﬂudarabine, and CMV infection pre-
ceded the diagnosis of GVHD in each case where both
conditions occurred. No statistically signiﬁcant differ-
ence in the rate of infection could be shown between
patients with and without GVHD [16].
Recent observations suggest that the choice of
nonmyeloablative conditioning regimen may inﬂu-
ence the timing and risk factors for CMV infection.
Using case-matched control patients, Junghanss et al.
[17] showed that while the incidence of a combined
end-point of CMV viremia and disease was the same
after 1 year for recipients of myeloablative and non-
myeloablative stem cell transplantations, nonmyelo-
ablative transplantation recipients were at much lower
risk over the ﬁrst 100 days. However, more cases of
CMV infection were observed late in the ﬁrst year
after nonmyeloablative transplantations. Median time
to CMV infection for recipients of nonmyeloablative
transplantations who received conditioning with ﬂu-
darabine and 200 cGy of total body irradiation was
130 days compared with 52 days for recipients of
conventional transplants (P.02). The authors hy-
pothesized that residual-host T lymphocytes may con-
tribute to resistance to CMV disease and that, as the
levels of these cells decline over the ﬁrst year follow-
ing transplantation, the risk of infection increases. In
these patients, GVHD was a highly signiﬁcant risk
factor for the development of CMV infection [17]. In
contrast, recent observations from 4 British transplan-
tation centers suggest that patients given nonmyelo-
ablative conditioning regimens containing Cam-
path-1H for in vivo T-cell depletion are at risk for
early CMV infection. Using a polymerase chain reac-
tion-based assay, the median time to CMV infection
reported in this series was only 27 days, with all but 1
initial episode occurring within the ﬁrst 100 days. No
correlation with GVHD was observed in the British
cohort [18]. In our series of patients, who were also
conditioned with in vivo T-cell depletion, we ob-
served that CMV infection occurred at a median of 53
days posttransplantation, and that all initial episodes
of antigenemia occurred within the ﬁrst 100 days. We
have similarly been unable to show a statistically sig-
niﬁcant correlation between GVHD or steroid use
and infection of CMV. The likely explanation for this
observation is that extensive T-cell depletion is a
strong risk factor for CMV infection, even in the
absence of GVHD.
Although our strategy of preemptive therapy for
antigenemic patients was highly effective at prevent-
ing the emergence of invasive CMV disease, extended
treatment with ganciclovir was poorly tolerated, pri-
marily because of myelosuppression. Several patients
developed CMV infection on more than 1 occasion,
often in conjunction with reduction in the dose of
ganciclovir for myelosuppression. In all cases, viremia
resolved with reinstitution of full-dose ganciclovir and
no nucleoside analogue resistance was documented.
Previous work has shown that ganciclovir-induced
neutropenia places patients at risk for bacterial infec-
tions [12]. Although no relationship between late neu-
tropenia and gram-negative infection could be found
in this cohort, late neutropenia remains a signiﬁcant
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cause of concern. The development of antiviral agents
active against CMV without the myelosuppressive side
effects of ganciclovir and the development of novel
methods of preventing and treating CMV infection
may result in more effective and better tolerated ther-
apies that prevent the emergence of latent virus infec-
tions.
Bacterial infections were a frequent occurrence in
our patients. The most common early bacterial infec-
tion in the posttransplantation period was bacteremia
with coagulase-negative staphylococci, presumably re-
lated to the use of indwelling central venous catheters.
In a minority of cases, infection was documented on
swabs from nonsterile sites. In these cases, coloniza-
tion with coagulase-negative staphylococci could not
be distinguished from actual infection. Despite this
potential overestimation, the shift from a predomi-
nance of infections with gram-negative organisms to
one of gram-positive organisms in neutropenic pa-
tients has been well documented [19-21]. In this study,
the relative infrequency of gram-negative infections
during the ﬁrst 30 days was likely caused by the pro-
phylactic use of ﬂuoroquinolone antibiotics and the
low degree of mucositis that develops with this con-
ditioning regimen. Prophylaxis with ﬂuoroquinolones
has been shown to decrease the incidence of gram-
negative infection in patients undergoing treatment
for acute leukemia, although early mortality is not
affected [22,23]. We have observed that graft rejection
seemed to protect patients from bacterial infections. It
is possible that patients who rejected their grafts were
more immunocompetent at the time of transplanta-
tion, and were therefore predisposed toward both
graft rejection and improved defense against infection.
We are currently examining the kinetics of immune
reconstitution among patients who undergo bone
marrow transplantation using T-cell depleting anti-
bodies to clarify whether this is the case.
Fungal infections were a signiﬁcant late complica-
tion among our patients. In all cases Aspergillus infec-
tions occurred among patients with GVHD, often in
cases where this was refractory to standard immuno-
suppressive treatment. Five of 7 patients with Aspergil-
lus infections have died. Among recipients of myelo-
ablative allogeneic bone marrow transplantations, the
rate of invasive fungal infection present at autopsy has
been reported to be as high as 40% [24], and in a
clinical series Aspergillus infection rates were reported
to be 15% [25]. Rates of Aspergillus infection are
known to vary widely with the location of the trans-
plantation center, use of prophylaxis and protective
isolation, and the host’s degree of immunosuppres-
sion. Our results indicate that the risk of late Aspergil-
lus infections in patients undergoing nonmyeloabla-
tive bone marrow transplantation is similar to that
seen in recipients of traditional transplants. Aspergillus
remained the most common infectious cause of death
despite the use of nonmyeloablative conditioning and
a relatively short duration of neutropenia. Many pa-
tients on this study had early exposure to corticoste-
roids for treatment of GVHD and engraftment syn-
drome. These drugs have been shown to increase the
rate of growth of Aspergillus colonies in vitro and to
decrease host resistance to these organisms [26]. The
high incidence of invasive Aspergillus infections in this
cohort suggests a need for improved antifungal prophy-
laxis with activity against ﬁlamentous organisms in re-
cipients of T lymphocyte depleted transplants. There
were no cases of invasive disease with Candida species,
reﬂecting the use of ﬂuconazole antifungal prophylaxis.
Our results indicate that patients with advanced
leukemia and lymphoma who have undergone non-
myeloablative stem cell transplantation remain at sig-
niﬁcant risk of developing opportunistic infections.
The patients in this study were extensively pretreated
and had refractory hematologic malignancies at the
time of enrollment. At the time of study entry many
patients were profoundly immunodeﬁcient, which was
indicated by the occurrence of infections with Alter-
naria and Roseomonas species within 1 week of trans-
plantation in 2 patients. There was a constant rate of
bacterial infection over the ﬁrst 100 days posttrans-
plantation. Relapse and GVHD did not seem to con-
tribute to the emergence of these bacterial infections.
Rates of CMV infection, Nocardia, and fungal infec-
tions were comparable to those reported by other
centers for recipients of myeloablative transplants. Al-
though GVHD may have contributed to the develop-
ment of fungal infections, no correlation with CMV
infection could be found. It is conceivable that in this
group of profoundly in vivo T-cell depleted patients a
quantitative deﬁciency of T cells may place patients at
signiﬁcant risk of CMV and other infections, even in
the absence of GVHD. T-cell add-back, in the form of
DLI, did not seem to reduce the risk of infection, and
was associated with an increase in the frequency of CMV
infection. Studies currently underway at our institution
examining the kinetics of immune reconstitution may
help explain these observations. Patients remained at risk
for serious infections for an extended period of time after
transplantation; Listeria and Nocardia infections were
documented in some patients more than 1 year after
treatment. Novel strategies to prevent these infections,
including transfer of donor-derived CMV-speciﬁc cyto-
toxic T lymphocytes [27] and other methods of promot-
ing immune reconstitution may improve the tolerability
and decrease the rate of serious infections seen among
recipients of these transplants.
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